NICE Protelos guidance remains unchanged after court-ordered re-examination
This article was originally published in Scrip
Executive Summary
NICE, the health technology institute for England and Wales, is sticking with its original recommendations on Servier's Protelos (strontium ranelate) for preventing osteoporotic fractures. Another final appraisal determination published yesterday follows a legal challenge from Servier and a Court of Appeal ruling that NICE review its guidance and give clear reasoning about why it reached a different conclusion from that of the EMA.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.